NeuroVive Pharmaceutical AB
SE-221 84 Lund
About NeuroVive Pharmaceutical ABNeuroVive Pharmaceutical is a pioneer in mitochondrial research and development. The focus is on developing drug candidates that maintain mitochondrial integrity and improves their function for indications with unmet medical needs. Research and development is conducted both in-house and in collaboration with renowned international partners.
Founder: Eskil Elmér
CEO: Erik Kinnman
CSO and Founder: Eskil Elmér
155 articles with NeuroVive Pharmaceutical AB
The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT.
Presentations will be made by members of NeuroVive's management and board as well as by external authorities in genetic mitochondrial diseases.
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to severe traumatic brain injury, TBI, has received Fast Track designation from the US Food and Drug Administration, FDA, facilitating its clinical development and path forwards to market.
NeuroVive Pharmaceutical AB announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333, NeuroVive's candidate drug for chronic treatment of genetic mitochondrial diseases, following successful completion of the first part.
NeuroVive Pharmaceutical AB announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT in development for treatment of moderate to severe traumatic brain injury, TBI.
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website www.neurovive.com.
NeuroVive Pharmaceutical AB today announced that the first healthy volunteer in the company's KL1333 phase Ia/b study has been screened and will be enrolled into the study.
NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
NeuroVive Pharmaceutical AB announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova, Sweden's innovation agency, and the Swelife call, for intensified development in the NVP015 project, the goal of which is to advance the candidate compound NV354 to clinical studies.
NeuroVive Pharmaceutical AB today announced that it has received approval of its clinical trial application concerning a planned phase I KL1333 study in patients and healthy volunteers from the UK regulatory authority, Medicines and Healthcare products Regulatory Agency (MHRA).
NeuroVive Pharmaceutical AB today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company's investigational compound NeuroSTAT.
NeuroVive Pharmaceutical AB today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical development plan for the treatment of moderate to severe Traumatic Brain Injury (TBI) at a pre-IND (Investigational New Drug) meeting.
NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia
NeuroVive Pharmaceutical AB today announced that scientists at the company's research partner the Children's Hospital of Philadelphia (CHOP) have received a three-year grant (W81XWH-17-PRMRP-TTDA), in total of $4,090,281 USD, from the U.S. Department of Defense
NeuroVive out-licenses targeted LHON therapy to BridgeBio
NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics
NeuroVive Pharmaceutical AB and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under NeuroVive's NVP015 program
NeuroVive Pharmaceutical AB announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharmaceutical AB, approved at the Extraordinary General Meeting on 22 March 2018.
NeuroVive decided to conduct a rights issue for the continued development of the company's drug projects following shareholder approval at an Extraordinary General Meeting.
NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced positive topline results after data base lock in the phase I single ascending dose (SAD) clinical study of KL1333, a novel treatment in clinical development for orphan genetic mitochondrial diseases.
NeuroVive Pharmaceutical AB announced a partnership with TRACK-TBI.
NeuroVive Pharmaceutical AB today on 27 April 2018 held its Annual General Meeting (AGM).
NeuroVive Pharmaceutical AB today on 27 April 2018 held its Annual General Meeting (AGM). A summary of the resolutions follows.